Ironwood Pharmaceuticals, Inc. - (IRWD) News
Filter IRWD News Items
IRWD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IRWD News Highlights
- IRWD's 30 day story count now stands at 2.
- Over the past 7 days, the trend for IRWD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AG and LAW are the most mentioned tickers in articles about IRWD.
Latest IRWD News From Around the Web
Below are the latest news stories about IRONWOOD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBioBOSTON, December 12, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the "Squeeze-Out Merger") pursuant to which VectivBio Holding AG ("VectivBio") has been merged with and into Ironwood Pharmaceuticals GmbH ("Merger Sub"), a wholly-owned subsidiary of Ironwood organized under the laws of Switzerland. As a result of the Squeeze-Out Merger, all remaining outstand |
Shareholders have faith in loss-making Ironwood Pharmaceuticals (NASDAQ:IRWD) as stock climbs 9.7% in past week, taking five-year gain to 2.3%While not a mind-blowing move, it is good to see that the Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) share price... |
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus ManagementDallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. ... |
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare ConferenceBOSTON, November 21, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call TranscriptIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript November 9, 2023 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.09 EPS, expectations were $0.17. Operator: Thank you for standing by. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone […] |
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesIronwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line. |
Q3 2023 Ironwood Pharmaceuticals Inc Earnings CallQ3 2023 Ironwood Pharmaceuticals Inc Earnings Call |
Ironwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year GuidanceThird Quarter 2023 Financial Results and Business Highlights |
Top 11 Extreme Value Stocks To BuyIn this article, we discuss the top 11 extreme value stocks to buy. To skip the detailed analysis and performance history of value stocks, go directly to the Top 5 Extreme Value Stocks To Buy. Value investing is an investment strategy that aims to find stocks that the market underestimates and are trading below their […] |
Ironwood Pharmaceuticals Reports Third Quarter 2023 ResultsBOSTON, November 09, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2023 results and recent business performance. |